Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer

Official record

Identifier

NCT02191761

Recruiting locations

country

United States

Interventions studied

SM04755

Lead sponsor

Biosplice Therapeutics, Inc.

Target enrolment

13 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Completed

First posted

Jul 16, 2014

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Subjects with advanced colorectal, gastric, hepatic or pancreatic cancer
* Subjects must have recovered from all toxicity associated with previous chemotherapy, targeted therapy, or radiotherapy
* Subjects must meet certain laboratory criteria
* Expected survival \> 3months
* Subjects must have no uncontrolled intercurrent illness

Exclusion Criteria:

* Women who are pregnant or lactating, or who are of childbearing potential , and men who do not use a barrier method
* Subjects with significant cardiac issues
* Subjects using certain medications
* Subjects with certain medical conditions
* Subjects with brain metastasis
* Subjects who have recently been enrolled in other experimental clinical trials of investigational agents

Indexed under

Colorectal Cancer